In a phase 2 study of patients with locally advanced mismatch repair–deficient colon cancer, treatment with neoadjuvant nivolumab plus ipilimumab resulted in a 98% pathological response rate and a 68% pathological complete response rate, with no recurrence of disease observed over a median follow-up of 26 months.

In a phase 3 trial, osimertinib significantly improved median progression-free survival to 39.1 months in patients with unresectable stage III EGFR-mutated NSCLC following chemoradiotherapy, compared to 5.6 months with placebo.

A phase 3 trial comparing neoadjuvant ipilimumab plus nivolumab followed by surgery to adjuvant nivolumab alone in resectable stage III melanoma patients found a significantly higher event-free survival rate in the neoadjuvant group. This suggests that pre-surgical immunotherapy could lead to better patient outcomes.

In a phase 2b trial, plozasiran significantly reduced fasting triglyceride levels at 24 weeks in patients with mixed hyperlipidemia, with the 50 mg quarterly dose achieving a mean reduction of 62.4 percentage points. This study highlights the potential of APOC3 inhibition as a therapeutic strategy for lipid management.

A 70-year-old diabetic woman presented with epigastric pain and was diagnosed with a transmural anteroseptal myocardial infarction complicated by a left ventricular thrombus. Using an image, this case reinforces the critical importance of recognizing and managing late-presenting myocardial infarction.

In lung transplant recipients presenting with acute respiratory symptoms, a broad differential diagnosis and prompt, comprehensive evaluation are crucial. This case highlights the significance of considering opportunistic infections and the necessity of early empiric antimicrobial therapy to prevent rapid deterioration.